AOL23h
The Oncology Bet Is Already Paying Off For Pfizer
On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the ...
Nasdaq6d
Smart Money Is Betting Big In MRNA Options
Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Avidity Biosciences jumps 16%; reaches all-time high
Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. (NASDAQ:MRNA) will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.
Nasdaq10d
Moderna is Now Oversold (MRNA)
In trading on Monday, shares of Moderna Inc (Symbol: MRNA) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $53.41 per share. By comparison ...
Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza ...
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Nasdaq6d
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.
Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...